Initial Patient Perspectives on Novel Radiation Dermatitis Intervention: Single-Center Experience

Introduction

Radiation dermatitis presents challenges in radiotherapy, with conventional treatments often falling short in severe cases. Silverlon, a recent innovation, shows promise in managing this condition. This study aims to explore patient perspectives on Silverlon's effectiveness in radiation dermatitis management.

Methods

Eleven patients undergoing breast or head and neck radiation participated, with two excluded for protocol non-compliance. Patients used Silverlon at various treatment stages and completed surveys on ease of use, compliance, concurrent use with emollients, skin effects, and pain relief.

Results

Seven patients with complete data were included in the final analysis: five underwent head and neck radiation, while two underwent breast radiotherapy. Treatment fractionation schemes ranged from 15 – 33 with all patients beginning use of Silverlon after CTCAE grade 1 dermatitis. Patients were surveyed after a week of use. All patients were protocol compliant but ease of use, varied, with four head and neck patients experiencing difficulties, due to product displacement. Adverse effects, including rash exacerbation and allergic reactions, were reported by two patients. However, some patients noted benefits such as a cooling effect and aid in wound healing, with two patients reporting pain relief.

Conclusion

Overall, breast cancer patients viewed Silverlon more favorably, likely due to its compatibility with bra attachment. This preliminary data suggests Silverlon's efficacy, especially in breast cancer cases, warranting further investigation through a proof of concept trial. Silverlon shows promise in managing radiation dermatitis, particularly in breast cancer patients, with potential for further refinement and= clinical application.